Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this measurement will automatically be reported upon conclusion of each visual field test. visual field testing is estimated to take 5-15 minutes for each visual field test. testing will occur every two weeks for the six-month study period.
Awards & highlights
No Placebo-Only Group
Summary
This trial will assess patient adherence and feelings on a novel web-based visual field test over 6 months. Participants will use iPads to complete tests at home, with researchers sending reminders and returning to the office to compare results.
Who is the study for?
This trial is for glaucoma patients aged 18-100 who speak English and have a visual acuity of at least 20/80. It's not suitable for those with severe astigmatism, central vision-affecting diseases, or neurocognitive/psychiatric disorders that could interfere with testing.
What is being tested?
The study tests the EyeSimplify web-based visual field test on iPads to see if patients will stick to biweekly home testing over six months and how it compares to standard office-based tests in detecting glaucoma progression.
What are the potential side effects?
Since this trial involves non-invasive at-home visual field testing using an iPad application, there are no direct medical side effects associated with the intervention.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ this measurement will automatically be generated after five eyesimplify visual field tests and is updated with each subsequent test. this metric will be recorded upon completion of the six-month study period.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this measurement will automatically be generated after five eyesimplify visual field tests and is updated with each subsequent test. this metric will be recorded upon completion of the six-month study period.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
EyeSimplify Self-Test Adherence
EyeSimplify Self-Test Persistence
Secondary study objectives
EyeSimplify User Experience Question #1 - "Please select what type of device you used to take your EyeSimplify visual field tests."
EyeSimplify User Experience Question #10 - "How much anxiety or concern did you have about your test performance while using the EyeSimplify online visual field test?"
EyeSimplify User Experience Question #11 - "How confident were you taking the EyeSimplify visual field test by yourself at home?"
+18 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
All patients will be in a single arm: patients will have one or both eyes (dependent on inclusion/exclusion criteria) tested with the EyeSimplify visual field test biweekly for 6 months.
Find a Location
Who is running the clinical trial?
Andrew Pouw, MDLead Sponsor
1 Previous Clinical Trials
52 Total Patients Enrolled
1 Trials studying Glaucoma
52 Patients Enrolled for Glaucoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a condition that affects my central vision.I do not speak English.I am physically unable to perform certain medical tests.I am between 18-100 years old and may have glaucoma.
Research Study Groups:
This trial has the following groups:- Group 1: Single Arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger